Latest from Incanthera

ICT01-2588 MHRA Scientific Advisory Meeting

Incanthera, the drug development and targeted cancer medicines company, (“Incanthera” or “the Company”), is delighted to announce the outcome of a scientific advisory meeting with the Medicines and Healthcare products Regulatory Agency (MHRA) for ICT01-2588, the Company’s lead product (candidate).

The MHRA was presented with an overview of the ICT01-2588 development plan, including its safety package to date.

Based on the positive and encouraging results presented to the MHRA, the MHRA has endorsed the Company’s ICT01-2588 development strategy to support Incanthera progressing to a Clinical Trial Authorisation (CTA) application.

The Company is thrilled with the successful outcome of the meeting and will now continue the development of ICT01-2588 towards the Phase 1 first time in human clinical trial.

Simon Ward, Chief Executive Officer of Incanthera, commented:

“This is excellent news. 

The feedback from the MHRA in reviewing the proposed development plan for our lead product, ICT01-2588, provides great confidence in what we believe to be ground breaking technology in oncology and cancer therapeutic treatments.

We now look forward to progressing the product further towards the Phase 1 clinical trial.”

 For further information, please contact:

Tim McCarthy, Chairman 07831 675747

Simon Ward, Chief Executive Officer 07747 625506

Montgomery Communications

Suzanne Brocks 07776 234600


Notes to Editors

Established in 2010, Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.

Operating from Manchester, with research facilities in Bradford and Salford, Incanthera was established from the University of Bradford’s Institute of Cancer Therapeutics ( to develop oncology treatments from a low cost base via a productive pipeline of early stage technology opportunities. 

Managed by a team of experienced individuals drawn from commercial, scientific and regulatory backgrounds, the team also has experience in the establishment, growth and exit of small to medium sized companies.

The website at has been designed to showcase the Company’s outstanding expertise in cancer therapeutic technologies.